Wladimir Hogenhuis
Vermogen: 472 716 $ op 31-10-2026
Vermogen: 472 716 $ op 31-10-2026
Dr. Wladimir Hogenhuis is a President, Chief Executive Officer & Director at Driver Bioengineering, Inc. and an Independent Director at Rezolute, Inc. He is on the Board of Directors at Driver Bioengineering, Inc., Rezolute, Inc., GATT Technologies BV and IHP Therapeutics, Inc. Dr. Hogenhuis was previously employed as a Chief Operating Officer by Ultragenyx Pharmaceutical, Inc., a Senior Vice President by GlaxoSmithKline Plc, and a General Manager-Neuroscience by Merck & Co., Inc. He also served on the board at Vision 2020.
He received his MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from the University of Leiden.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
REZOLUTE, INC. 0,12% | 05-10-2026 | 119.675 ( 0,12% ) | 472 716 $ | 31-10-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| REZOLUTE, INC. | Directeur/Bestuurslid | 02-03-2021 |
Driver Bioengineering, Inc.
Driver Bioengineering, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered immune cell therapies for cancer | Algemeen Directeur | 28-04-2022 |
GATT Technologies BV
GATT Technologies BV Medical SpecialtiesHealth Technology Develops a soluble surgical tape | Directeur/Bestuurslid | 01-05-2020 |
IHP Therapeutics, Inc. | Directeur/Bestuurslid | - |
| Bedrijven | Functie | Einde |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Operationeel Directeur | 10-01-2020 |
| GSK PLC | Corporate Officer/Principal | 01-09-2018 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Vision 2020 | Directeur/Bestuurslid | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 10 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University of Leiden
University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vision 2020 | |
Rezolute, Inc.
Rezolute, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for metabolic diseases related to chronic glucose imbalance | Health Technology |
GATT Technologies BV
GATT Technologies BV Medical SpecialtiesHealth Technology Develops a soluble surgical tape | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Driver Bioengineering, Inc.
Driver Bioengineering, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered immune cell therapies for cancer | Health Technology |
IHP Therapeutics, Inc. |
Kies jouw editie
Alle financiële informatie op nationaal niveau